canisters in controlled environment storage
i2c Pharmaceutical Services holds a patent for a unique formulation approach for HFA pMDI. Details are published in "Aerosol Composition", WO99/51205 (US Patent number 6737044). Extensive in-vitro characterisation of formulations manufactured using this technique have been undertaken.

In summary, the use of the novel formulation approach for HFA suspension systems permits:

  • Low engergy dispersion of micronised drug particles.
  • Robust pMDI formulations.
  • Good aerosol performance.
  • Applicable to a variety of drugs: Salbutamol Sulphate, Fluticasone Propionate, Formoterol Fumarate, Budesonide, Budesonide/Formoterol combination and Salmeterol Xinafoate/Fluticasone Propionate combination.
  • Improved manufacturing processes.
  • Non-pulmonary depositing excipients.
i2c pharmaceutical services is actively seeking partners to participate in further development of this robust, versatile, technology. Please contact us for further information.